Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: A prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS

Journal of Clinical Oncology

Volumn 30, Issue 35, 2012, Pages 4317-4322

  Dupuis, Jehan ^a   Berriolo Riedinger, Alina ^b   Julian, Anne ^d   Brice, Pauline ^e   Tychyj Pinel, Christelle ^f   Tilly, Hervé ^g   Mounier, Nicolas ^h   Gallamini, Andrea ^m   Feugier, Pierre ⁱ   Soubeyran, Pierre ^j   Colombat, Philippe ^k   Laurent, Guy ^d   Berenger, Nathalie ^e   Casasnovas, Rene Olivier ^c   Vera, Pierre ^g   Paone, Gaetano ^h   Xerri, Luc ^l   Salles, Gilles ^f   Haioun, Corinne ^a   Meignan, Michel ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c HÔPITAL DU BOCAGE   (France)

^d CHU PURPAN   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g CENTRE HENRI BECQUEREL   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ CHU NANCY BRABOIS   (France)

^j INSTITUT BERGONIÉ   (France)

^k UNIVERSITY HOSPITAL OF TOURS   (France)

^l INSTITUT PAOLI CALMETTES   (France)

^m S CROCE E CARLE HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84870735307     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.0934     Document Type: Article

References (32)

1. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
2. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007 (Pubitemid 46972781)
3. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824-4831, 2008
4. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
5. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
6. Bachy E, Brice P, Delarue R, et al: Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: Effect of response quality on survival - A study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol 28:822-829, 2010
7. Meignan M, Gallamini A, Haioun C, et al: Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 51:2171-2180, 2010
8. Juweid ME, Stroobants S, Hoekstra OS, et al: Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578, 2007 (Pubitemid 350002965)
9. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
10. Meignan M, Gallamini A, Meignan M, et al: Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50:1257-1260, 2009
11. Jerusalem G, Beguin Y, Najjar F, et al: Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 12:825-830, 2001 (Pubitemid 32655093)
12. Karam M, Novak L, Cyriac J, et al: Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107:175-183, 2006 (Pubitemid 43939045)
13. Wöhrer S, Jaeger U, Kletter K, et al: 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 17:780-784, 2006
14. Weiler-Sagie M, Bushelev O, Epelbaum R, et al: (18)F-FDG avidity in lymphoma readdressed: A study of 766 patients. J Nucl Med 51:25-30, 2010
15. Zinzani PL, Musuraca G, Alinari L, et al: Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 7:291-295, 2007 (Pubitemid 46408194)
16. Bishu S, Quigley JM, Bishu SR, et al: Predictive value and diagnostic accuracy of F-18-fluorodeoxyglucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 48:1548-1555, 2007 (Pubitemid 47272805)
17. Janikova A, Bolcak K, Pavlik T, et al: Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma? Clin Lymphoma Myeloma 8:287-293, 2008
18. Le Dortz L, De Guibert S, Bayat S, et al: Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 37:2307-2314, 2010
19. Trotman J, Fournier M, Lamy T, et al: Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 29:3194-3200, 2011
20. Solal-Celigny P, Lepage E, Brousse N, et al: Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma: Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 329:1608-1614, 1993 (Pubitemid 23345639)
21. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
22. Kuhnowski F, Thieblemont C, Jardin F, et al: A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma. J Clin Oncol 28:575s, 2010 (suppl 15; abstr 8010)
23. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
24. Meignan M, Itti E, Bardet S, et al: Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol 27:2739-2741, 2009
25. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Cox D: Regression model and lifetables. J R Stat Soc Ser B 34:187-220, 1972
27. Kramer MS, Feinstein AR: Clinical biostatistics: LIV. The biostatistics of concordance. Clin Pharmacol Ther 29:111-123, 1981
28. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: First report of the national LymphoCare study. J Clin Oncol 27:1202-1208, 2009
29. Lopci E, Santi I, Derenzini E, et al: FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: Multicentric study. Ann Oncol 21:1877-1883, 2010
30. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al: SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118:37-43, 2011
31. Gallamini A, Patti C, Viviani S, et al: Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 152:551-560, 2011
32. Le Gouill S, De Guibert S, Planche L, et al: Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 96:1128-1135, 2011